,A review on generation of real-world evidence

被引:0
|
作者
Shunmugavelu, Meenakshi Sundaram [1 ]
Panda, Jayanta Ku [2 ]
Sehgal, Ashish [3 ]
Makkar, Brij Mohan [4 ]
机构
[1] Trichy Diabet Specialty Ctr, Trichy 620018, Tamil Nadu, India
[2] SCB Med Coll Odisha, Cuttack, Odisha, India
[3] Diabet Med, New Delhi, India
[4] Cleveland Clin, Adv Certificate Courses Diabet, New Delhi, India
来源
CLINICAL DIABETOLOGY | 2021年 / 10卷 / 05期
关键词
real-world evidence; healthcare policies; real-world data; pragmatic trials; policy making; RANDOMIZED CONTROLLED-TRIALS; INSULIN DEGLUDEC; BASAL INSULIN; MULTICENTER; LIMITATIONS; POPULATION; THERAPY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-world evidence can generate credible evidence to inform treatment decisions. Real-world evidence is in developmental stage and is fast evolving yet there are many unexplained attributes of real-world evidence. Real-world evidence informs benefit-risk decisions and is increasingly being used to support regulatory decision making. Potential benefits of real-world data include determination of extended outcomes including long-term outcomes, opportunities to partner with patients in innovative ways, and reduction in time and cost to generate dependable evidence. Limitations of real-world evidence include uncertainty in the quality of datasets and lack methodologic rigor in real-world studies. Use of real-world evidence for healthcare practices and policies is limited. Ensuring completeness, homogeneity, and linkage of datasets can enhance utility for epidemiological investigations and improvement in health outcomes. Research should be strengthened for real-world studies and technical standards should be reinforced. Collaborations of stakeholders is key to formulation and adoption of guidance for real-world evidence. Real-world data cannot be a substitute to randomized clinical studies but can possibly augment the generated evidence.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 50 条
  • [31] Strategies to Address Current Challenges in Real-World Evidence Generation in Japan
    Laurent, Thomas
    Lambrelli, Dimitra
    Wakabayashi, Ryozo
    Hirano, Takahiro
    Kuwatsuru, Ryohei
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 167 - 176
  • [32] REAL-WORLD DATA AND REAL-WORLD EVIDENCE TERMINOLOGY HARMONIZATION: EVIDENCE GAPS AND FUTURE STEPS
    Chhaya, V
    Kumar, S.
    Khambholja, K.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S524 - S525
  • [33] Turning real-world data into real-world evidence: some practical guidance
    Schneeweiss, Sebastian
    [J]. PRAVENTION UND GESUNDHEITSFORDERUNG, 2023,
  • [34] Advancing regulatory science through real-world data and real-world evidence
    Cure, Pablo
    Fessel, Joshua P.
    Hartshorn, Christopher M.
    Steele, Scott J.
    [J]. JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 8 (01)
  • [35] What Does It Take to Transform Real-World Data Into Real-World Evidence?
    Ramamoorthy, Anuradha
    Huang, Shiew-Mei
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) : 10 - 18
  • [36] A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence
    Yixin Fang
    Hongwei Wang
    Weili He
    [J]. Therapeutic Innovation & Regulatory Science, 2020, 54 : 749 - 757
  • [37] Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness
    Corrigan-Curay, Jacqueline
    Sacks, Leonard
    Woodcock, Janet
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (09): : 867 - 868
  • [38] A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence
    Fang, Yixin
    Wang, Hongwei
    He, Weili
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (04) : 749 - 757
  • [39] Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review
    Khambholja, Kapil
    Gehani, Manish
    [J]. VALUE IN HEALTH, 2023, 26 (03) : 427 - 434
  • [40] Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea
    Lee, Hankil
    Ahn, Hyeon-Soo
    Kwon, Sol
    Kang, Hye-Young
    Han, Euna
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):